1. 53PImmune-related adverse events correlate with clinical outcomes in non-small cell lung cancer (NSCLC) patients treated with nivolumab in the Italian expanded access programme. (17th December 2018) Authors: Baldini, E; Lunghi, A; Cortesi, E; Turci, D; Garassino, M C; Stati, V; Ardizzoni, A; Ricciuti, B; Frassoldati, A; Romano, G; Illiano, A; Verderame, F; Fasola, G; Marchetti, P; Pinto, C; Carteni, G; Scotti, V; Tibaldi, C; Fioretto, L; Giannarelli, D Journal: Annals of oncology Issue: Volume 29(2018)Supplement 10 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. LBA2 First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC: Safety, pharmacokinetics (PK) and immunogenicity in CASPIAN. (15th December 2019) Authors: Özgüroğlu, M; Goldman, J W; Reinmuth, N; Chen, Y; Dvorkin, M; Trukhin, D; Statsenko, G; Hotta, K; Ji, J H; Hochmair, M J; Voitko, O; Havel, L; Poltoratskiy, A; Losonczy, G; Verderame, F; Thomas, M; Zheng, Y; Lloyd, A; Jiang, H; Paz-Ares, L Journal: Annals of oncology Issue: Volume 30(2019)Supplement 11 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗